Replies to post #188452 on Biotech Values

[caravon]

If ENTA's NS5a is inferior to ABBV NS5a, there is no need even talk about it.

However, if ENTA's NS5a is superior to ABBV NS5a, there is a good possibility combining it with
Gild or MRK nucs, etc., driving Abbv out of future HCV business.

Finally, Abbv can be interested to include ENTA's NS5a into Abbv own Next-Gen 2 combo. After all, the field is very competitive.